Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 |
| Dec 19, 2016 |
| clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00744718 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | completed | Phase 2 | 73 | Vejle HospitalOTHER | 1 | Nov 16, 2016 | clinicaltrials |
| NCT01630018 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | completed | Phase 2 | 141 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00112086 | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | completed | Phase 2 | 56 | Japan Clinical Oncology GroupOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00710762 | A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01246440 | Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | completed | Phase 2 | 39 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT00129727 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | completed | Phase 2 | 62 | Massachusetts General HospitalOTHER | 0 | Jun 1, 2016 | clinicaltrials |
| NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | completed | Phase 2 | 78 | Cancer Research UKOTHER | 1 | May 24, 2016 | clinicaltrials |
| NCT00002558 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | completed | Phase 1 / Phase 2 | 108 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT00423852 | Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | completed | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02324595 | Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study(MISSION) | completed | Phase 2 | 30 | Catholic University of the Sacred HeartOTHER | 1 | Apr 13, 2016 | clinicaltrials |
| NCT00170664 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 129 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01033123 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | completed | Phase 2 | 41 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033292 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 43 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01460979 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | completed | Phase 2 | 47 | AGO Study GroupOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | completed | Phase 2 | 23 | Daniela Matei, MDOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00284427 | Safety of Antioxidants During GYN Cancer Care | completed | Phase 2 | 25 | Jeanne Drisko, MD, CNS, FACNOTHER | 0 | Feb 10, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer(PITCH) | completed | Phase 1 / Phase 2 | 21 | Leiden University Medical CenterOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00588237 | Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer(MITO-5) | completed | Phase 2 | 26 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 36 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00719212 | Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 61 | Translational Research in OncologyOTHER | 7 | Jan 11, 2016 | clinicaltrials |
| NCT00008138 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer(S0009) | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 0 | Jan 8, 2016 | clinicaltrials |
| NCT00246688 | Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 63 | BayerINDUSTRY | 0 | Dec 31, 2015 | clinicaltrials |
| NCT00031954 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT00453310 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT01313078 | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00791778 | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 246 | BayerINDUSTRY | 14 | Sep 28, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | completed | Phase 2 | 110 | Boehringer IngelheimINDUSTRY | 5 | Aug 13, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2016source: clinicaltrials